1 Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, Carbuccia N et al. AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions
Acute myeloid leukemia (AML) with abnormal bone marrow eosinophils and with inv(16)(p13q22) or t(16;16)(p13;q22) leading to a CBFB-MYH11 fusion gene have been defined as a distinct entity by the World Health Organization classification and are associated with a favorable outcome. The CBFB-MYH11 fusion proteins are interfering in a dominant-negative manner with core binding factor (CBF), thereby impairing hematopoietic differentiation and predisposing cells to leukemic transformation. However, knock-in mouse models have demonstrated that CBFB-MYH11 alone is not sufficient to cause a leukemic phenotype and that additional aberrations were essential for the development of AML. 1 Secondary cytogenetic abnormalities occur in B40% of cases with þ 22, þ 8 (10-15% each), and del(7q) or þ 21 is most commonly observed. Recent molecular analyses have also provided important insights into the pathogenesis of myeloid disorders, and the commonly detected mutations of KIT and NRAS genes as well as deregulated CEBPA expression have been identified as likely candidates for cooperating events in CBF-positive AML. 2, 3 Recently, exon 8 splice site mutations in the gene encoding the E3-ligase CBL have been reported in three cases with inv(16), suggesting an alternative mechanism of activating tyrosine kinases, as mutant CBL may act as a dominant-negative protein by inhibiting proper downregulation of activated tyrosine kinases, such as KIT and FLT3. 4 This study was performed to further decipher accompanying genetic lesions at the molecular level in AML with CBFB-MYH11 rearrangements. Therefore, chromosome banding analyses, single-nucleotide polymorphism (SNP) array analyses and comprehensive screening for mutations in the genes KIT, NRAS, KRAS, FLT3, CBL, PTPN11 and JAK2 were performed in 37 newly diagnosed AML with CBFB-MYH11 rearrangement. Details on patient's characteristics are provided in the Supplementary Information. Patients gave their informed consent for this investigation. The study abides by the rules of the local Internal Review Board and the tenets of the revised Helsinki protocol. Chromosome banding analysis was available in all cases. In total, 30 cases showed an inv(16)(p13q22), whereas in 5 cases a t(16;16)(p13;q22) was observed. Two patients showed a normal karyotype with a cryptic CBFB-MYH11 rearrangement confirmed by reverse transcriptase PCR. Using standard chromosome banding analysis, additional cytogenetic aberrations were observed in 13 cases with de novo AML and in 1 case with t(therapy-related)-AML (37.8%). Karyotypes of patients with additional chromosome aberrations are depicted in the Supplementary Information (Supplementary Table S1 ). Recurring additional aberrations were
and del(7q) (n ¼ 2). Gains and losses as well as large regions of copyneutral loss of heterozygosity detected by SNP array analysis are depicted in detail in Table 1 . Detailed information on chromosomal gains and losses identified by SNP arrays as compared with chromosome banding analysis are provided in the Supplementary Information. A 7q deletion was observed in a total of four cases. Two of these were detected by SNP array analyses only; they were missed by cytogenetics because of their small size. On the basis of SNP array data, the commonly deleted region was identified to range from 7q36.1 to 7q36.3 (size: 8.5 Mb; physical map position 147 549 804-156 038 680). In addition to a gain of the whole chromosome 8, which was frequently observed as an additional aberration, SNP array analyses revealed only a partial gain on 8q in one case, which was missed by cytogenetics because of the small size ranging from 8q24.13 to 8q24.3 (size: 25.3 Mb; physical map position 120 986 982-146 268 936). Furthermore, a recurrent deletion (n ¼ 2) on chromosome 18 was detected by SNP array, but not detected by cytogenetics. The commonly deleted region was localized in 18q23 (size: 3.1 Mb; physical map position 72 481 657-75 604 994). Most interestingly, in six cases a small deletion ranging from 0.46 to 2.18 Mb on 17q11 not visible by chromosome banding analysis was identified by SNP array analysis. The only gene included in the minimal deleted region was the NF1 gene. In two cases, the CBFB-MYH11 rearrangement was cryptic and could not be detected by chromosome banding analysis or fluorescent in situ hybridization (FISH) using two probes flanking the breakpoints within the CBFB gene. However, a CBFB-MYH11 transcript was amplified by reverse transcriptase PCR. In one of these cases, the SNP array data revealed a small gain on 16p13 including the 3 0 part of the MYH11 gene (size: 71 kb; physical map position 15 654 558-15 725 636), suggesting the insertion of additional 3 0 MYH11 sequences into the CBFB locus leading to the CBFB-MYH11 fusion gene.
It is interesting that five cases showed a deletion on 16p13 (sizes: 73, 236, 461, 462, 468, 888, 1481 kb). All cases included the 5 0 part of the MYH11 gene, and in four cases the ABCC1 gene (multidrug resistance-associated protein 1) was included in Letters to the Editor the deleted region, which could have an impact on prognosis. The patient with the smallest deletion in 16p13 also showed a deletion on 16q22 including the 3 0 part of CBFB (size: 35 kb, physical map position 65 672 864-65 707 954). These deletions are comparable to the findings in chronic myeloid leukemia and other leukemia subtypes in which also small deletions in the breakpoint region of BCR and ABL or the respective genes involved in rearrangements have been described. In all analyzed cases with 7q deletion, 18q deletion and 8q24 gain SNP array data were confirmed by interphase FISH (details are given in the online Supplementary Information). In all six cases with NF1 deletion detected by SNP array analysis, interphase FISH confirmed the respective deletion. Details on the size of the minimal deleted region and location of the FISH probe are depicted in Supplementary Figure S1 in the Supplementary Information. The proportion of cells showing an NF1 deletion varied between 17 and 80%, demonstrating that the NF1 deletion was acquired. In patients 9 and 13, a small residual NF1 signal was detectable as the FISH probe extended the deleted region on the telomeric side.
Results of an extensive mutation analyses are depicted in Table 2 and in more detail in Supplementary Table S2 (Supplementary Information). Mutation analyses revealed an internal tandem duplication (ITD) within the FLT3 gene in three cases, and in three additional cases, a mutation within the tyrosine kinase domain (TKD). Within the KIT gene, a D816V mutation was detected in five cases and a D816Y and a D816_K818delinsVN in one each, whereas mutations in exon 8 were observed in further two cases. Mutations in NRAS were found in codon 12 in six cases and in codon 61 in another eight patients. All the five KRAS mutations were in codon 12, whereas no mutation was found in codon 61. In four cases, an exon 8 þ 9 splice mutation in CBL was detected. Two additional cases showed and exon 8 splice mutation. In none of the 37 patients, a JAK2V617F mutation was observed. Six cases without any of these mutations referred to above and also without NF1 deletion were analyzed for PTPN11 mutations. Yet, no PTPN11 mutation was detected in these cases.
Overall, 46 alterations were observed in the genes NF1, NRAS, KRAS, KIT, FLT3 and CBL. Two of these genes were affected in 10 cases, and in one case three genes (NRAS, CBL and NF1) (Supplementary Table S2 ). FLT3-ITD and FLT3-TKD were accompanied by NRAS mutations in two cases and one case, respectively. In addition, NRAS mutations were accompanied by KIT mutations in two cases and by NF1 deletion, and CBL mutation in one case each. A combination of KIT mutation and NF1 deletion was observed once and one case each showed a KRAS mutation in combination with a CBL mutation or NF1 deletion, respectively. For details see Supplementary Table S1 in the Supplementary Information and Figure 1 . Mainly on the basis of the data from juvenile myelomonocytic leukemia, it was hypothesized that alterations of NF1 and RAS are functionally equivalent and therefore most likely mutually exclusive; however, recently it was shown in mice that NF1 deficiency cooperates with oncogenic K-RAS to induce AML. 5 Gilliland 6 suggested a model for AML in which the so-called class I mutations, such as activating mutations in receptor tyrosine kinases, which provide a proliferative and/or survival signal to hematopoietic progenitors, have to be accompanied by so-called class II mutations. The latter ones target hematopoietic transcription factors and serve primarily to impair differentiation and subsequent apoptosis. CBFB-MYH11 rearrangement is a typical class II mutation leading to inhibition of the CBF transcription factor complex, thereby blocking early myeloid differentiation. Class I mutations such as KIT and NRAS mutations in addition to CBFB-MYH11 rearrangement have been reported by Bullinger et al. 7 in 8 of 34 (24%) and 14 of 34 (41%) cases investigated, whereas FLT3-ITD was detected in 1 of 46 (2%) and FLT3-TKD in 7 of 45 (15%) of cases. Bacher et al. 2 detected NRAS mutations in 50 of 133 (37.6%) and FLT3-TKD in 6 of 119 (5%) patients with inv(16)/t(16;16), and Schnittger and colleagues found no FLT3-ITD in 47 cases. Paschka et al. 3 reported KIT mutations in 29.5% of AML cases with CBFB-MYH11 rearrangement and observed an association with a higher risk of relapse and inferior survival. We revealed in our study that 34 of 37 CBFB-MYH11-positive AML harbor mutations within the RAS genes (KRAS, NRAS) or alterations in genes regulating RAS (FLT3, KIT, CBL and NF1). The frequencies in our cohort presented here are comparable to published data with mutations observed in KIT (24.3%), NRAS (38.9%), Table 2 Results of mutation analysis Figure 1 Association of cytogenetic and molecular genetic abnormalities in 37 patients with CBFB-MYH11-positive patients at primary diagnosis.
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FLT3-ITD (8.1%) and FLT3-TKD (8.3%
). In addition, we found KRAS mutations in 13.5% of cases, not accompanied by mutations in one of the above-mentioned genes. Furthermore, we identified exon 8/9 splice mutations in the CBL gene in 6 of 37 cases. Exon 8 splice site mutation has been reported recently in 3 of 61 cases with inv(16) and in 2 of 61 cases with t(8;21). In addition, it was shown that the CBL exon 8 splice variant was absent in four independent remission samples of one patient with t(8;21), providing evidence that exon 8 splice variant are acquired and AML associated. 4 The mutant CBL splice variant without exon 8 results in an in-frame deletion, which encodes a CBL protein lacking a part of the conserved linker region, including two essential tyrosine residues, and almost the entire ring finger, which is critical for E3-ligase activity. This suggests that mutant CBL may act as a dominant-negative protein by inhibiting proper downregulation of critical activated tyrosine kinases, such as KIT and FLT3.
In addition and most interestingly, our whole-genome screening approach using SNP arrays revealed a high frequency of deletions of the NF1 gene (six cases). The NF1 gene encodes neurofibromin, a guanosine triphosphotase (GTPase)-activating protein that negatively regulates the p21ras (Ras) family of signaling proteins by accelerating GTP hydrolysis. The NF1 gene is thought to be a tumor suppressor gene. Germline loss-offunction mutations of NF1 lead to the neurofibromatosis type I (synonym: von Recklinghausen's disease), which is an autosomal-dominant disorder with a prevalence of B1:3000 worldwide. Carriers of the mutations develop benign neurofibromas and café-au-lait spots and are predisposed to neuronal tumors and to juvenile myeloid neoplasms, which include juvenile myelomonocytic leukemia, myelodysplasia and AML. In approximately 50-60% of children with neurofibromatosis developing myeloid leukemias, loss of heterozygosity of the normal NF1 allele is observed. In other cases, a mutant NF1 allele causes truncation and functional disability of the protein, neurofibromin 1. In addition, in children suffering from chronic myelomonocytic leukemia (CMML) without germline NF1 mutations, acquired loss of function mutations of NF1 have been reported.
In contrast, the role of NF1 in adult AML has not been studied in detail so far. Only few cases and only a limited number of exons have been analyzed for NF1 mutations. The 17q11.2 deletions including the NF1 gene have been detected by array comparative genomic hybridization (CGH) in 6 of 100 consecutive de novo AML cases, four showing a complex aberrant karyotype and two an inv(16). In another study, in 18 out of 60 AML with complex aberrant karyotype, a commonly deleted region on 17p11-17q11 between 23.1 and 29.5 Mb including the NF1 gene was identified using array CGH.
On the other hand, the incidence of RAS mutations in AML has been studied by several groups. Activating mutations in the RAS protooncogenes occur overall in between 12 and 27% of de novo AML. However, RAS-dependent pathways can also be activated by alterations in other genes (that is, FLT3, KIT, NF1, CBL and PTPN11) (Figure 2) . Recently, Neubauer et al. 8 demonstrated that patients with de novo AML harboring RAS mutations are significantly less likely to experience relapse when treated with high-dose cytarabine (HDAC) as postremission therapy as compared with low-dose cytarabine. Furthermore, they observed among patients receiving HDAC that those with RAS mutations also had a lower risk of relapse than patients with the wild-type RAS. In addition, it was shown that among younger patients with AML(o60 years) receiving HDAC as induction therapy, activated RAS proteins predicted for a significantly higher response rate and longer overall survival. Furthermore, it is established that patients with AML and CBFB-MYH11 rearrangement also benefit from treatment with HDAC. Our data show that the majority of cases (92%) with CBFB-MYH11 rearrangement show alterations activating the RAS pathway. Therefore, the good response of CBFB-MYH11-positive AML to HDAC may be due to the high incidence of molecular alterations leading to an activation of the RAS pathway.
Several therapeutic agents have been developed that target RAS proteins or components of their upstream or downstream signaling pathways. Farnesyltransferase inhibitors prevent the post-translational attachment of the farnesyl isoprenoid group to RAS and thereby inhibit its correct localization to the plasma membrane that is essential to initiate signal transduction. In addition, several kinase inhibitors have been developed that act downstream of RAS targeting the RAF/MAPK pathway or the Letters to the Editor PI3K/AKT pathway, respectively. Inhibitors of RAS-processing enzymes and agents that interfere with the activation of downstream effectors such as MEK have already been evaluated. Our data point to the possibility that these new drugs provide a potential to increase the cure rate in CBFB-MYH11-positive AML, which may be evaluated in prospective clinical trials.
In conclusion, CBFB-MYH11 rearrangements are accompanied in more than 90% of cases by alterations leading to an activation of the RAS pathway because of mutations within the RAS genes (KRAS, NRAS) themselves or alterations in genes regulating RAS (FLT3, KIT, CBL, NF1). NF1 was identified by SNP arrays as a new target gene in AML with CBFB-MYH11 and was found to be deleted in 16% of cases in our cohort. These data underline that alterations of the RAS pathway have an important role in CBFB-MYH11-positive AML pathogenesis and furthermore may explain the favorable response to HDAC. New treatment approaches for CBFB-MYH11-positive AML patients with drugs also targeting the RAS pathway should be considered in future clinical trials, as the majority of patients with CBFB-MYH11-positive AML might benefit from such targeted approach. Polycythemia vera (PV), a myeloproliferative neoplasm (MPN), is characterized by the presence of a mutated, activated form of the tyrosine kinase JAK2. 1 In 95% of cases, PV patients present the V617F mutation in exon 14 (JAK2-V617F) and half of V617F-negative PV patients carry mutations or deletions in exon 12.
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2 Both types of mutations result in activation of JAK2 and STAT5. Recently the 46/1 (or 'GGCC') haplotype of chromosome 9p was found associated with a pre-disposition to JAK2 mutations in the same allele. As this haplotype is relatively frequent, unrecognized mutations of JAK2 may not be rare. Indeed healthy donors were reported positive for JAK2-V617F using nested PCR assays, and the repeated occurrence of the V617F mutation of JAK2 has been demonstrated in essential thrombocythemia (ET) and in PV. [3] [4] [5] In addition, in 2 PV patients, JAK2-V617F and mutations in exon 12 of JAK2 co-existed in separate sub-clones originating from a single progenitor in one case, or from unrelated hematopoietic stem cells in the other case.
6,7 V617F-positive PV patients with additional mutation(s) in exon 14 of JAK2 (V615L, C616Y, C618R and D620E) are also evidence of multiple JAK2 mutations. 8 As different JAK2 mutants may have different JAK2 activity, the JAK2 mutational status may influence subclone outcome and affect disease phenotype.
To address this question, we studied 3 PV patients found to be carriers of a new mutation in exon 14 of JAK2, leucine 611 changed for a valine (L611V) present in cis with V617F, that resulted in the double JAK2-L611V/V617F mutant. DNA and RNA extracted from purified granulocytes, platelets, CD3 þ T-lymphocytes and colonies were analyzed using allele-specific quantitative PCR assays (AS-qPCRs), pyrosequencing and
